Last reviewed · How we verify
Ovide (MALATHION)
Ovide (MALATHION) is a cholinesterase inhibitor small molecule developed by TARO PHARMS NORTH and currently owned by Taro. It targets the melatonin receptor type 1A and is approved by the FDA for the treatment of pediculosis capitis since 1982. As an off-patent medication, Ovide is available as a generic from multiple manufacturers. Key safety considerations include its potential toxicity and environmental concerns. Commercially, Ovide is available as a generic medication.
At a glance
| Generic name | MALATHION |
|---|---|
| Sponsor | Taro |
| Drug class | Cholinesterase Inhibitor [EPC] |
| Target | Melatonin receptor type 1A |
| Modality | Small molecule |
| Therapeutic area | Neuroscience |
| Phase | FDA-approved |
| First approval | 1982 |
Approved indications
- Pediculosis capitis
Common side effects
- second-degree burns
- chemical burns
- mild conjunctivitis
- contact allergic sensitization
- skin irritation
- scalp irritation
Key clinical trials
- Impact of Community Scabies Treatment on Head Lice Prevalence in the Solomon Islands (PHASE3)
- Pediatric Head Lice Study Product Comparison (PHASE2)
- Safety and Tolerability of a Novel Malathion Formulation in Children Age 6-24 Months With Head Lice (PHASE2,PHASE3)
- Efficacy, Safety and Tolerability of a Novel Malathion Formulation in Patients 2 Years and Older With Head Lice (PHASE3)
- Efficacy, Safety and Tolerability of a Novel Malathion Formulation in Patients 2 Years and Older With Head Lice (PHASE3)
- Pharmacokinetics of Malathion Gel 0.5% and Malathion 0.5% Lotion (Ovide) in Patients With Head Lice (PHASE1)
- Safety and Efficacy of a Novel Malathion Formulation in the Treatment of Head Lice (PHASE3)
- Safety and Tolerability of a Novel Malathion Formulation in Infants and Toddlers With Head Lice (PHASE2)
Patents
| Patent | Expiry | Type |
|---|---|---|
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
| FDA Orange Book | Patents + exclusivity |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ovide CI brief — competitive landscape report
- Ovide updates RSS · CI watch RSS
- Taro portfolio CI